PHILADELPHIA — Pre-clinical microdosing studies aimed at gauging the activity of investigational drugs in humans on a metabolic and pharmacokinetic level, commonly referred to as “Phase 0” studies, won’t predict whether a drug candidate will succeed or fail at higher doses and in broader populations, a Novartis exec said last week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.